CLS’s acting CEO Dan J. Mogren returns to work after medical leave

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announced that the company’s acting CEO Dan J. Mogren returns to work from April 1st, after a planned medical leave from February 10th until March 31st.

“I underwent a routine heart valve replacement procedure that required some weeks of recovery. The surgery and recovery have gone very well, and I look forward to coming back to work in full power”, said Dan J. Mogren, acting CEO of CLS.

Dan J. Mogren replaces deputy CEO Lars-Erik Eriksson, who will continue his role as CFO.

Contact Information:
Dan J. Mogren, acting CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40 E-mail: dan.mogren@clinicallaser.com

About CLS and TRANBERG system

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG^®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT^®, the Company's interstitial laser thermotherapy for immunostimulating ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: www.clinicallaser.se

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-04-2022 16:00 CET.